Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and efficacy of intravenous administration of intermittent doses of levosimendan (infusions of 0,2 μg/kg/min, of levosimendan or placebo, without bolus, for 6 hours every 2 weeks) compared to placebo in ambulatory patients with advanced chronic heart failure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Parc de Salut Mar
• Treatments: Simendan

Criteria

Inclusion Criteria:

• qged more than 18,

• left ventricular ejection fraction below 35%,

• diagnostic criteria of advanced chronic heart failure.

Exclusion Criteria:

• Conduction abnormalities (auricular ventricular block),

• malignant arrythmias,

• recent administration of inotropic drugs,

• recent acute coronary syndrome,

• recent cerebrovascular accident,

• glomerular filtration rate below 30,

• systolic blood pressure below 90 mmhg.